- $2.62m
- $8.44m
- $0.05m
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 02:32 PM
NASDAQ RESUMED AT 10:28 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 10:23 AM
NASDAQ RESUMED AT 09:38 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:33 AM
HCW Biologics Q1 revenue surges on licensing deal
Brief: HCW Biologics Discovers That HCW11-040 Prevents Bronchopulmonary Dysplasia During IND-Enabling Studies
Brief: Hcw Biologics Delivers A Major Update For Its T-Cell Engager Program Revealing Mechanism Of Action
HCW Biologics Q4 revenue drops sharply on license suspension
Brief: Hcw Biologics Closes Exclusive Worldwide License For Hcw11-006 – A High Potential Fusion Immunotherapeutic
NASDAQ RESUMED AT 12:48 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 12:43 PM
Brief: HCW Biologics Regains Compliance With All Continued Listing Rules For Nasdaq Per Nasdaq Determination Letter
Brief: Hcw Biologics And Wy Biotech Announce Closing Of First Round Of Financing For Newly Formed Joint Venture Trimmune
Brief: Hcw Biologics Announces Warrant Inducement Agreement
Brief: Hcw Biologics Announces Initiation Of First-In-Human Clinical Trial To Evaluate Hcw9302 In An Autoimmune Disease
Brief: HCW Biologics Says Substantial Doubt Exists Regarding Ability To Continue As Going Concern For At Least 12 Months
David Di Pilla's HCW fund surges on partially deferring Healthscope rental payments
Brief: HCW Biologics Announces 1-For-40 Reverse Stock Split